RESUMO
Air pollution is associated with elevated cardiovascular mortality and an increase in cardiovascular risk factors. However, the literature data on associations between air pollution and cardiovascular risk factors are contradictory. To explore the relationship between residential exposure to atmospheric pollutants and cardiovascular risk factors (lipid biomarker and blood pressure levels). We studied a sample of 2339 adult participants in the ELISABET study from the Dunkirk and Lille urban areas of France. The mean annual exposure to atmospheric pollutants (PM10, NO2 and SO2) at the home address was estimated via an air dispersion model. The associations were probed in multivariate linear regression models. The mean NO2 level was 26.05 µg/m3 in Lille and 19.96 µg/m3 in Dunkirk. The mean PM10 level was 27.02 µg/m3 in Lille and 26.53 µg/m3 in Dunkirk. We detected a significant association between exposure to air pollutants and the high-density lipoprotein (HDL) (which is a protective factor against cardiovascular diseases) level: for a 2 µg/m3 increment in PM10, the HDL level decreased by 1.72% (p = 0.0037). None of the associations with other lipid variables or with blood pressure were significant. We didn't find evidence significant associations for most of the risk factors but, long-term exposure of adults to moderate levels of ambient air pollution was associated with a decrement in HDL.
Assuntos
Poluentes Atmosféricos , Poluição do Ar , Doenças Cardiovasculares , Exposição Ambiental , Material Particulado , Humanos , França/epidemiologia , Masculino , Feminino , Pessoa de Meia-Idade , Adulto , Poluentes Atmosféricos/análise , Poluição do Ar/efeitos adversos , Doenças Cardiovasculares/epidemiologia , Material Particulado/análise , Idoso , Pressão Sanguínea , Fatores de Risco de Doenças Cardíacas , Fatores de Risco , Dióxido de Nitrogênio/análise , Dióxido de Enxofre/análiseRESUMO
Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2-7). Median time between two reinjections was 57 days (IQR 28-82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9% of dosages (93/95) and above 8 mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.